; and (xi) perform such other duties as the Secretary determines appropriate. (D) Substance use disorder treatment analysis Not later than 2 years after the date of the enactment of the Strengthening the Health Care Fraud Prevention Task Force Act of 2018, the trusted third party with a contract in effect under subparagraph (B) shall perform an analysis of aberrant or fraudulent billing patterns and trends with respect to providers and suppliers of substance use disorder treatments from data shared with the partnership. (E) Executive Board (i) Executive Board composition (I) In general There shall be an executive board of the partnership comprised of representatives of the Federal Government described in subclause (III) and representatives of the private sector described in subclause (IV). (II) Chairs The executive board shall be co-chaired by one Federal Government official and one representative from the private sector. (III) Federal Government representatives (aa) Required members The executive board shall consist of the following members (or designees of the following) from the Federal Government: (AA) The Administrator of the Centers for Medicare & Medicaid Services. (BB) The Deputy Attorney General for the Department of Justice. (CC) The Deputy Secretary of the Department of Health and Human Services. (DD) The Inspector General for the Department of Health and Human Services. (EE) The Director of the Federal Bureau of Investigation. (bb) Permissive additional members If determined by unanimous consent of the members of the executive board, the board may include other Federal or State Government representation as appropriate, including senior-level representation from the TRICARE Management Activity, the Department of Veterans Affairs, the Office of Personnel Management, State Medicaid agencies, and State medicaid fraud control units. (IV) Private sector membership (aa) In general The executive board shall consist of at least three senior-level representatives from various private sector health care related